The estimated Net Worth of Lloyd A Rowland is at least $1.31 Million dollars as of 20 August 2024. Mr. Rowland owns over 11,250 units of CytomX Therapeutics Inc stock worth over $176,821 and over the last 10 years he sold CTMX stock worth over $35,756. In addition, he makes $1,097,840 as Senior Vice President, Chief Compliance Officer, General Counsel, and Secretary at CytomX Therapeutics Inc.
Lloyd has made over 8 trades of the CytomX Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 11,250 units of CTMX stock worth $14,738 on 20 August 2024.
The largest trade he's ever made was exercising 11,250 units of CytomX Therapeutics Inc stock on 20 August 2024 worth over $14,738. On average, Lloyd trades about 2,347 units every 87 days since 2014. As of 20 August 2024 he still owns at least 134,978 units of CytomX Therapeutics Inc stock.
You can see the complete history of Mr. Rowland stock trades at the bottom of the page.
Lloyd A. Rowland is Senior Vice President, Chief Compliance Officer, General Counsel, Secretary of the Company. Mr. Rowland brings 25 years of biotechnology and pharmaceutical industry legal counsel and transactional experience to CytomX. From August 2014 until February 2017, Mr. Rowland held the position of senior vice president, general counsel, secretary and chief compliance officer of Xencor, a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Prior to Xencor, Mr. Rowland, over a twelve-year career at Amylin Pharmaceuticals, held various roles, most recently as vice president and chief compliance officer and formerly, as vice president, general counsel and secretary. During his time as general counsel at Amylin, he directed all corporate legal and compliance affairs for the company including the launch of two pharmaceutical products. Prior to joining Amylin, Mr. Rowland served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland received his B.S. degree in economics and political science from Southern Methodist University, and his J.D. from Emory University School of Law.
As the Senior Vice President, Chief Compliance Officer, General Counsel, and Secretary of CytomX Therapeutics Inc, the total compensation of Lloyd Rowland at CytomX Therapeutics Inc is $1,097,840. There are 3 executives at CytomX Therapeutics Inc getting paid more, with Sean McCarthy having the highest compensation of $3,769,930.
Lloyd Rowland is 63, he's been the Senior Vice President, Chief Compliance Officer, General Counsel, and Secretary of CytomX Therapeutics Inc since 2018. There are 5 older and 12 younger executives at CytomX Therapeutics Inc. The oldest executive at CytomX Therapeutics Inc is Frederick W. Gluck, 86, who is the Co-Founder & Independent Director.
Lloyd's mailing address filed with the SEC is C/O CYTOMX THERAPEUTICS, INC., 151 OYSTER POINT BLVD., STE. 400, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 9 years, insiders at CytomX Therapeutics Inc have traded over $57,157,858 worth of CytomX Therapeutics Inc stock and bought 662,000 units worth $7,876,720 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Harbor Master Investors (Ca..., and James E Deerfield Mgmt L.P..... On average, CytomX Therapeutics Inc executives and independent directors trade stock every 20 days with the average trade being worth of $48,707. The most recent stock trade was executed by Jeffrey B Landau on 20 August 2024, trading 11,250 units of CTMX stock currently worth $14,738.
cytomx is an oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its probody technology platform. the company uses the platform to create development-stage proprietary cancer immunotherapies against clinically-validated targets, as well as to develop first-in-class investigational cancer therapeutics against novel targets. cytomx believes that its probody platform has the potential to improve the combined efficacy and safety profile of monoclonal antibody modalities, including cancer immunotherapies, antibody drug conjugates and t-cell-recruiting bispecific antibodies. probody therapeutics are designed to take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues. investigational probody therapeutics are being developed that address clinically-validated cancer targets in immuno-oncology, such as pd-l1 against which o
CytomX Therapeutics Inc executives and other stock owners filed with the SEC include: